Genoscience PharmaGenoscience Pharma
  • Home
  • About Us
    • Mission
    • History
    • Board of Directors
    • Scientific Advisory Board
    • Leadership Team
  • Science
    • Approach
    • Pipeline
    • Primary Liver Cancers
    • Secondary Liver Cancers
    • Collaborations
    • Publications & Abstracts
  • Medical Info
    • Overview
    • Patient Organizations
    • Professional Organizations
  • Investors
  • News
    • News
    • Events
  • Contact Us
    • Contact
    • Careers
GENOSCIENCE PHARMA out licenses rights of GNS561 in Europe, US and Canada territories in Cholangiocarcinoma
News

GENOSCIENCE PHARMA out licenses rights of GNS561 in Europe, US and Canada territories in Cholangiocarcinoma

Genoscience is proud to announce the out-licensing of GNS561 in the cholangiocarcinoma in the United States / Canada and Europe territories to GENFIT. It is a new starting point for the company and GNS561.
GENFIT will start a Phase 2 program in 2022 in cholangiocarcinoma.
Genoscience Pharma will pursue its development in other oncology indications.
#oncology #development #autophagy

211217 – Genoscience deal PR ENG

211217 – Genoscience deal PR FR

GNS561, a clinical-stage PPT1 inhibitor is efficient against Hepatocarcinoma via modulation of lysosomal functions
Next Post

GNS561, a clinical-stage PPT1 inhibitor is efficient against Hepatocarcinoma via modulation of lysosomal functions

GNS561, a clinical-stage PPT1 inhibitor is efficient against Hepatocarcinoma via modulation of lysosomal functions

You have a question ?

Contact us

Would you like to meet us ?

Next events

Menu

  • Home
  • About Us
  • Science
  • Pipeline
  • Collaborations
  • Investors
  • News
  • Contact Us

Social

twitter twitter

Legals

  • Legal Notice
  • Home
  • About Us
    • Mission
    • History
    • Board of Directors
    • Scientific Advisory Board
    • Leadership Team
  • Science
    • Approach
    • Pipeline
    • Primary Liver Cancers
    • Secondary Liver Cancers
    • Collaborations
    • Publications & Abstracts
  • Medical Info
    • Overview
    • Patient Organizations
    • Professional Organizations
  • Investors
  • News
    • News
    • Events
  • Contact Us
    • Contact
    • Careers